Medical DevicesLast reviewed April 2026

Biocompatibility(Biocompatibility)

The ability of a medical device material to perform its intended function without causing adverse biological response in contact with tissue, blood, or other body fluids.

Usage Examples

Biocompatibility testing per ISO 10993-1 included cytotoxicity, sensitization, and irritation endpoints for the skin-contact device.
Chemical characterization under ISO 10993-18 replaced traditional in vivo systemic toxicity studies.

What is Biocompatibility?

Biocompatibility evaluation is required for medical devices that contact the body directly or indirectly. The international standard ISO 10993 (adopted by FDA via 21 CFR 820 and by EU MDR) defines the framework: risk-based assessment followed by in vitro and in vivo testing as indicated.

The contact category (surface, external communicating, implant) and duration (limited, prolonged, long-term) drive the required endpoints: cytotoxicity, sensitization, irritation, systemic toxicity, genotoxicity, implantation, hemocompatibility, and carcinogenicity. Chemical characterization per ISO 10993-18 increasingly substitutes for some animal testing. Biocompatibility data appears in 510(k), De Novo, and PMA submissions and is a common source of FDA deficiency questions when testing is incomplete or assessment is weak.

Regulatory Context

This term appears most often in medical devices workflows where submission quality, regulatory evidence, and audit readiness depend on consistent language. It is commonly referenced alongside ISO 10993, 21 CFR 820, EU MDR.

FDA CDRHEMAHealth Canada

When This Matters

Biocompatibility testing per ISO 10993-1 included cytotoxicity, sensitization, and irritation endpoints for the skin-contact device.
Chemical characterization under ISO 10993-18 replaced traditional in vivo systemic toxicity studies.

Common Mistakes

Using drug-only submission assumptions for device regulatory pathways.
Ignoring post-market obligations in pre-market planning.
Weak predicate and classification rationale in dossier narratives.

Related Regulations

ISO 1099321 CFR 820EU MDR

Frequently Asked Questions

Driven by contact type and duration per ISO 10993-1 decision framework. Short surface contact may need only cytotoxicity, sensitization, irritation. Long-term implants need additional endpoints including implantation, genotoxicity, and potentially carcinogenicity.

Increasingly yes under ISO 10993-18 (2020). Characterization of extractables and leachables combined with toxicological risk assessment can substitute for some traditional in vivo endpoints. FDA and EU regulators accept this approach when properly justified.

Whenever a device contacts the body directly or indirectly through fluid paths. Non-contacting devices (external monitors, some imaging equipment) may require limited or no biocompatibility testing based on risk assessment.